Clinical trial
Insulin Glulisine in Diabetes Mellitus, Type 2
NCT00174668 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00174668 |
|---|---|
| Title | Insulin Glulisine in Diabetes Mellitus, Type 2 |
| Official title | 52-week, Open, Randomized, Multinational, Multicenter Clinical Trial Comparing Insulin Glulisine in Combination With Insulin Glargine in an Intensified Insulin Regimen to a Two-injection Conventional Insulin Regimen in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control Pretreated With a… |
| Acronym | GINGER |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Insulin Glulisine, Insulin Therapy, Insulin Glargine |
| Enrollment | 311 |
| Start date | Nov 1, 2004 |
| Primary completion | Nov 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | Sep 15, 2009 |
| Countries | Australia, Belgium, Czechia, France, Germany, Italy, Netherlands, Poland, Portugal, Romania, Slovakia, Spain and 3 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: